Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

The need for large-scale randomized evidence

C Baigent1

  • 1Clinical Trial Service Unit, Radcliffe Infirmary, Oxford, UK.

British Journal of Clinical Pharmacology
|April 1, 1997
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Long-term safety and efficacy of anacetrapib in patients with atherosclerotic vascular disease.

European heart journal·2021
Same author

Effect on non-vascular outcomes of lowering LDL cholesterol in patients with chronic kidney disease: results from the Study of Heart and Renal Protection.

BMC nephrology·2017
Same author

Coxibs, Traditional NSAIDs, and Cardiovascular Safety Post-PRECISION: What We Thought We Knew Then and What We Think We Know Now.

Clinical pharmacology and therapeutics·2017
Same author

Blood pressure lowering and major cardiovascular events in people with and without chronic kidney disease: meta-analysis of randomised controlled trials.

BMJ (Clinical research ed.)·2013
Same author

Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials.

Lancet (London, England)·2013
Same author

Parenteral anticoagulants in heart disease: current status and perspectives (Section II). Position paper of the ESC Working Group on Thrombosis-Task Force on Anticoagulants in Heart Disease.

Thrombosis and haemostasis·2013
Same journal

The quantification and epistemology of medicines use and polypharmacy tested in an observational study.

British journal of clinical pharmacology·2026
Same journal

Cardiovascular and neuropsychiatric outcomes with PCSK9 inhibitors in atherosclerotic cardiovascular disease: A retrospective cohort study.

British journal of clinical pharmacology·2026
Same journal

Flucloxacillin plasma and urinary concentrations with and without probenecid and urinary biomarker profiles in healthy volunteers.

British journal of clinical pharmacology·2026
Same journal

Cardiovascular and neuroendocrine dynamics in antibiotic dose individualization in intensive care.

British journal of clinical pharmacology·2026
Same journal

Safety of swallowed corticosteroids and their influence on the hypothalamic-pituitary-adrenal gland axis and on markers of bone resorption and formation in patients with eosinophilic esophagitis.

British journal of clinical pharmacology·2026
Same journal

A regulatory perspective on the first approved EU application to reformulate an inhaled medicine with a gas propellant with reduced global warming potential.

British journal of clinical pharmacology·2026
See all related articles

Large randomized trials are essential for detecting moderate health outcome differences from treatments. Smaller or non-randomized studies are unreliable for assessing treatment effects, necessitating larger sample sizes in future research.

Area of Science:

  • Clinical Trials
  • Evidence-Based Medicine
  • Health Outcomes Research

Background:

  • Reliable detection of moderate treatment effects on major health outcomes requires robust evidence.
  • Existing smaller or non-randomized studies often lack the power to distinguish moderate benefits, hazards, or negligible differences.

Purpose of the Study:

  • To emphasize the necessity of large-scale randomized evidence for accurate assessment of moderate treatment effects.
  • To advocate for methodological changes in randomized trials to facilitate larger sample sizes.

Main Methods:

  • Discusses the limitations of small and non-randomized studies in detecting moderate outcome differences.
  • Proposes strategies for increasing sample sizes in randomized trials, including simplified designs and streamlined data collection.

Related Experiment Videos

  • Highlights the role of the 'uncertainty principle' in guiding participant eligibility for larger trials.

    • Main Results:

    • Large-scale randomized trials, or meta-analyses of smaller trials, are crucial for reliable detection of moderate health outcome differences.
    • Small or non-randomized studies are generally insufficient for distinguishing moderate treatment effects (benefit, hazard, or negligible difference).

    Conclusions:

    • Future randomized trials must adopt methods promoting larger sample sizes to reliably detect moderate improvements in major health outcomes.
    • Simplified trial designs and streamlined data collection are key to achieving the necessary scale for robust evidence generation.